OCULAR THERAPEUTIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.745 USD | +12.98% |
|
-9.10% | +6.39% |
| Apr. 18 | Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup | DJ |
| Apr. 18 | Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 189.9 | 1,559 | 534 | 216.4 | 491.6 | 734.1 | - | - |
| Enterprise Value (EV) 1 | 189.9 | 1,380 | 421.2 | 168.1 | 491.6 | 734.1 | 734.1 | 734.1 |
| P/E ratio | -2.07 x | -8.09 x | -77.4 x | -2.9 x | -4.42 x | -5.45 x | -5.52 x | -5.89 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 44.9 x | 89.6 x | 12.3 x | 4.2 x | 8.41 x | 10.7 x | 8.66 x | 5.43 x |
| EV / Revenue | 44.9 x | 89.6 x | 12.3 x | 4.2 x | 8.41 x | 10.7 x | 8.66 x | 5.43 x |
| EV / EBITDA | -2.28 x | -25.9 x | -7.06 x | -2.83 x | -6.19 x | -8.61 x | 0.52 x | 14 x |
| EV / FCF | -2.38 x | -28.7 x | -8 x | -3.42 x | -6.44 x | -11 x | -9.17 x | -13.2 x |
| FCF Yield | -42% | -3.49% | -12.5% | -29.3% | -15.5% | -9.06% | -10.9% | -7.59% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 48,080 | 75,302 | 76,610 | 77,010 | 110,219 | 154,704 | - | - |
| Reference price 2 | 3.950 | 20.70 | 6.970 | 2.810 | 4.460 | 4.745 | 4.745 | 4.745 |
| Announcement Date | 3/12/20 | 3/11/21 | 2/28/22 | 3/6/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.227 | 17.4 | 43.52 | 51.49 | 58.44 | 68.34 | 84.72 | 135.1 |
| EBITDA 1 | -83.27 | -60.07 | -75.62 | -76.54 | -79.4 | -85.28 | 1,422 | 52.48 |
| EBIT 1 | -85.8 | -62.85 | -78.04 | -78.65 | -82.38 | -99.61 | -104.9 | -70.63 |
| Operating Margin | -2,029.86% | -361.13% | -179.3% | -152.74% | -140.96% | -145.76% | -123.85% | -52.27% |
| Earnings before Tax (EBT) 1 | -86.37 | -155.6 | -6.553 | -71.04 | -80.74 | -102.4 | -111 | -74.22 |
| Net income 1 | -86.37 | -155.6 | -6.553 | -71.04 | -80.74 | -101.1 | -108.1 | -104.9 |
| Net margin | -2,043.34% | -894.31% | -15.06% | -137.95% | -138.14% | -147.97% | -127.61% | -77.63% |
| EPS 2 | -1.910 | -2.560 | -0.0900 | -0.9700 | -1.010 | -0.8714 | -0.8600 | -0.8050 |
| Free Cash Flow 1 | -79.82 | -54.4 | -66.74 | -63.32 | -76.32 | -66.5 | -80.03 | -55.73 |
| FCF margin | -1,888.24% | -312.56% | -153.36% | -122.96% | -130.59% | -97.31% | -94.47% | -41.25% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/11/21 | 2/28/22 | 3/6/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.15 | 12.31 | 13.19 | 12.27 | 11.96 | 14.08 | 13.37 | 15.19 | 15.08 | 14.8 | 15.36 | 16.46 | 17.54 | 18.97 | 23.77 |
| EBITDA 1 | -18.94 | -17.48 | -17.28 | - | -21.04 | -18.87 | -22.07 | -19.92 | -18.32 | - | -23 | -22 | -19 | -15 | -12 |
| EBIT 1 | -19.53 | -18.05 | -17.83 | -19.92 | -21.54 | -19.36 | -22.55 | -20.57 | -19.21 | -20.05 | -21.97 | -23.8 | -26.49 | -27.28 | -17.64 |
| Operating Margin | -160.69% | -146.63% | -135.23% | -162.37% | -180.06% | -137.55% | -168.6% | -135.45% | -127.41% | -135.45% | -143.04% | -144.59% | -151.02% | -143.82% | -74.22% |
| Earnings before Tax (EBT) 1 | 2.657 | -3.85 | -12.54 | -18.77 | -24.19 | -15.54 | -30.32 | -20.68 | -0.516 | -29.22 | -22.82 | -24.46 | -27.32 | -27.87 | -17.92 |
| Net income 1 | 2.657 | -3.85 | -12.54 | -18.77 | -24.19 | -15.54 | -30.32 | -20.68 | -0.516 | -29.22 | -22.6 | -24.2 | -26.85 | -27.55 | -17.92 |
| Net margin | 21.86% | -31.28% | -95.11% | -152.99% | -202.16% | -110.41% | -226.69% | -136.19% | -3.42% | -197.41% | -147.11% | -146.97% | -153.1% | -145.26% | -75.39% |
| EPS 2 | 0.0300 | -0.0500 | -0.1600 | -0.2400 | -0.3100 | -0.2400 | -0.3900 | -0.2600 | -0.0100 | -0.3500 | -0.2033 | -0.2117 | -0.2483 | -0.2517 | -0.1300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 2/28/22 | 5/9/22 | 8/8/22 | 11/7/22 | 3/6/23 | 5/8/23 | 8/7/23 | 11/7/23 | 3/11/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 179 | 113 | 48.3 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -79.8 | -54.4 | -66.7 | -63.3 | -76.3 | -66.5 | -80 | -55.7 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | -53% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | - | -0.8200 | 0.0700 | 0.0800 | - |
| Capex 1 | 2.24 | 0.84 | 1.19 | 3.72 | 6.09 | 10 | 5.75 | 5.8 |
| Capex / Sales | 52.95% | 4.83% | 2.74% | 7.21% | 10.42% | 14.63% | 6.79% | 4.29% |
| Announcement Date | 3/12/20 | 3/11/21 | 2/28/22 | 3/6/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.745
USD
Average target price
15.5
USD
Spread / Average Target
+226.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.39% | 734M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- OCUL Stock
- Financials Ocular Therapeutix, Inc.
